Emiko Sugiyama
- Oncology top 10%
- Pharmacology top 5%
- Molecular Biology
- Pharmacology top 2%
- Rheumatology top 10%
- Co-authors
- Yoshiro SaitoKouichi KuroseNahoko KaniwaRyuichi HasegawaJun‐ichi SawadaTakuji OkusakaNagahiro SaijoKeiko Maekawa
- Topics
- Pancreatic and Hepatic Oncology Research (8 papers)Drug-Induced Adverse Reactions (5 papers)Cancer Genomics and Diagnostics (5 papers)
- Cited by
- PharmacologyOncology
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Emiko Sugiyama
31 papers receiving 986 citations
Peers
Comparison fields: 5 of 96
- Oncology 395
- Pharmacology 260
- Molecular Biology 257
- Pharmacology 210
- Rheumatology 160
Countries citing papers authored by Emiko Sugiyama
This map shows the geographic impact of Emiko Sugiyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emiko Sugiyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emiko Sugiyama more than expected).
Fields of papers citing papers by Emiko Sugiyama
This network shows the impact of papers produced by Emiko Sugiyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emiko Sugiyama. The network helps show where Emiko Sugiyama may publish in the future.
Co-authorship network of co-authors of Emiko Sugiyama
This figure shows the co-authorship network connecting the top 25 collaborators of Emiko Sugiyama. A scholar is included among the top collaborators of Emiko Sugiyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emiko Sugiyama. Emiko Sugiyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 2 | |
| 3 | 81 | |
| 4 | 26 | |
| 5 | 190 | |
| 6 | 131 | |
| 7 | 1 | |
| 8 | 31 | |
| 9 | 49 | |
| 10 | 52 | |
| 11 | 29 | |
| 12 | 43 | |
| 13 | 5 | |
| 14 | 13 | |
| 15 | 29 | |
| 16 | 72 | |
| 17 | Chronic recurrent multifocal osteomyelitis showing marked improvement with corticosteroid treatment. | 21 |
| 18 | 21 | |
| 19 | Beneficial effects of interleukin-2 on natural killer activity in lung cancer patients. | 1 |
| 20 | A new record of Mammomonogamus auris from the middle ear of domestic cats in Japan. | 1 |
About Emiko Sugiyama
Emiko Sugiyama is a scholar working on Pharmacology, Oncology and Pharmacology, having authored 32 papers that have together received 1.0k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (8 papers), Drug-Induced Adverse Reactions (5 papers) and Cancer Genomics and Diagnostics (5 papers). The work is most often cited by research in Pharmacology (210 citations), Pharmacology (260 citations) and Oncology (395 citations). Emiko Sugiyama has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Yoshiro Saito, Kouichi Kurose, Nahoko Kaniwa, Ryuichi Hasegawa, Jun‐ichi Sawada, Takuji Okusaka, Nagahiro Saijo, Keiko Maekawa, Su-Ryang Kim and Junji Furuse. Their work appears in journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.